What are the main side effects of Thymosin Alpha-1?

Thymosin Alpha-1 side effects and warning signals include Generally well-tolerated, Mild injection site reactions, Rare flu-like symptoms, Occasional fatigue, and Not FDA-approved in the United States.

What evidence level is Thymosin Alpha-1?

Thymosin Alpha-1 is rated Level B; the listed research status is Phase 3.

Immune Support / Level B / Phase 3 / Last reviewed 2026-04-04

Thymosin Alpha-1 Evidence Guide

Thymosin Alpha-1 (Zadaxin) has Phase 3 data and is approved in over 30 countries for hepatitis B and as a cancer immune adjuvant, though it lacks FDA approval in the US. The hepatitis B evidence base - including 18+ RCTs - is real and reproducible. For immune restoration research in immunocompromised populations or viral hepatitis, thymosin alpha-1 is the best-evidenced peptide immune modulator in this library.

Our Take

Best for: Hepatitis B/C immune adjuvant therapy, cancer immune support, T-cell restoration in immunocompromised patients
Evidence grade: Level B
Confidence: Moderate
Starting point: 1.6mg subcutaneous twice weekly (standard clinical course: 6 months)

Benefits and Evidence

Hepatitis B/C Treatment: Level B, includes human evidence - Clinical trials demonstrate improved viral clearance and seroconversion rates in chronic hepatitis B and C when used as monotherapy or in combination with interferon.
Cancer Immune Adjuvant: Level B, includes human evidence - Garaci et al. (1995, Cancer) reported improved 1-year survival (57% vs. 28%) in 16 advanced melanoma patients combining thymalfasin 1.6 mg SC with dacarbazine; Cheng et al. (2005, Hepatogastroenterology) showed enhanced NK-cell and CD4+ counts in 60 HCC patients receiving thymalfasin adjunctive to TACE.
T-Cell Immune Restoration: Level B, includes human evidence - Consistently enhances T-cell counts and function in immunocompromised patients, including those with HIV and post-chemotherapy immunosuppression.

Side Effects and Warnings

Generally well-tolerated
Mild injection site reactions
Rare flu-like symptoms
Occasional fatigue
Not FDA-approved in the United States
Should be used with caution in autoimmune conditions
May potentiate immune responses in transplant recipients
Limited pediatric safety data

Research Dosage References

<strong>Subcutaneous injection</strong> - 1.6 mg - Twice weekly - Standard clinical dose used in hepatitis and oncology trials. Treatment courses typically last 6-12 months.
<strong>Subcutaneous injection</strong> - 0.8-3.2 mg - Daily to twice weekly - Dose varies by indication. Higher doses used in some oncology protocols.

Mechanism of Action

Thymosin Alpha-1 enhances immune function through multiple pathways: 1. T-cell maturation: Promotes differentiation of immature T-cells into functional CD4+ and CD8+ populations in the thymus. 2. Dendritic cell activation: Stimulates dendritic cell maturation via TLR9 signaling, improving antigen presentation. 3. NK cell enhancement: Increases natural killer cell cytotoxicity against virally infected and tumor cells. 4. Cytokine modulation: Balances Th1/Th2 immune responses, upregulating IL-2 and IFN-alpha while modulating inflammatory cytokines. 5. Regulatory T-cell induction: Promotes immune tolerance and reduces excessive inflammatory responses.

Legal Status

Thymosin Alpha-1 (Zadaxin) is approved in over 30 countries for hepatitis B and as an immune adjuvant. It is not FDA-approved in the United States but is available as a research peptide. Orphan drug designations have been granted for some indications.

Primary Sources

Thymalfasin (thymosin alpha 1) therapy in patients with chronic hepatitis B. Hepatology, 1998.
Thymosin alpha1 as an adjuvant therapy in hepatocellular carcinoma. Ann N Y Acad Sci, 2007.
Thymosin alpha 1: a comprehensive review of the literature. Expert Opin Biol Ther, 2010.